Reason for request
Inclusion
-
Clinical Benefit
Low |
the actual benefit of BETMIGA is low in the symptomatic treatment of urgency and increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder syndrome. This actual benefit is provisional pending the results of the study versus VESICARE. |
Clinical Added Value
no clinical added value |
BETMIGA does not procure an improvement in actual benefit (LAB level V, non-existent) in the symptomatic treatment of urgency and increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder syndrome and, in particular, pending the results of the study versus VESICARE. |